NCT04765449View on ClinicalTrials.gov

Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

July 29, 2022

Study Completion Date

January 19, 2023

Conditions
Covid19
Interventions
DRUG

Cytotoxic T Lymphocytes

Given IV. Cytotoxic T Lymphocytes collected from healthy volunteer donors who have recovered from COVID-19. The T cells are collected, manufactured to be COVID-specific, and stored frozen at Thomas Jefferson University.

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

All Listed Sponsors
collaborator

Tevogen Bio Inc

UNKNOWN

lead

Thomas Jefferson University

OTHER

NCT04765449 - Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection | Biotech Hunter | Biotech Hunter